BANK VONTOBEL/CALL/BIONTECH ADR/115/0.1/21.06.24 Share Price

Warrant

ON38V

DE000VM65XU9

Real-time Euronext Paris 10:04:02 23/05/2024 BST
0.213 EUR +106.80% Intraday chart for BANK VONTOBEL/CALL/BIONTECH ADR/115/0.1/21.06.24
Current month+255.17%
1 month+178.38%
Date Price Change
23/05/24 0.213 +106.80%
22/05/24 0.103 +390.48%
21/05/24 0.021 +23.53%
20/05/24 0.017 -5.56%
17/05/24 0.018 -10.00%

Real-time Euronext Paris

Last update May 23, 2024 at 10:04 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
ON38V
ISINDE000VM65XU9
Date issued 27/12/2023
Strike 115 $
Maturity 21/06/2024 (30 Days)
Parity 10 : 1
Emission price 0.81
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.365
Lowest since issue 0.014
Delta0.26x
Omega 11.31
Premium14.74x
Gearing43.08x
Moneyness 0.8896
Difference Strike 12.7 $
Difference Strike %+11.04%
Spread 0.01
Spread %4.46%
Theoretical value 0.2090
Implied Volatility 54.76 %
Total Loss Probability 79.01 %
Intrinsic value 0.000000
Present value 0.2090
Break even 117.27 €
Theta-0.06x
Vega0.01x
Rho0x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
94.41 EUR
Average target price
105.4 EUR
Spread / Average Target
+11.62%
Consensus
  1. Stock Market
  2. Warrants
  3. ON38V Warrant